Centene Corporation (CNC)
NYSE: CNC · Real-Time Price · USD
31.80
-0.84 (-2.57%)
At close: Sep 16, 2025, 4:00 PM EDT
31.85
+0.05 (0.16%)
Pre-market: Sep 17, 2025, 5:40 AM EDT
Centene Market Cap
Centene has a market cap or net worth of $15.62 billion as of September 17, 2025. Its market cap has decreased by -62.02% in one year.
Market Cap
15.62B
Enterprise Value
18.68B
1-Year Change
-62.02%
Ranking
Category
Stock Price
$31.80
Market Cap Chart
Since December 13, 2001, Centene's market cap has increased from $173.20M to $15.62B, an increase of 8,917.34%. That is a compound annual growth rate of 20.85%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Sep 15, 2025 | 16.03B | -47.59% |
Dec 31, 2024 | 30.58B | -22.85% |
Dec 29, 2023 | 39.64B | -14.63% |
Dec 30, 2022 | 46.44B | -3.41% |
Dec 31, 2021 | 48.08B | 38.14% |
Dec 31, 2020 | 34.81B | 33.79% |
Dec 31, 2019 | 26.02B | 9.87% |
Dec 31, 2018 | 23.68B | 36.01% |
Dec 29, 2017 | 17.41B | 80.27% |
Dec 30, 2016 | 9.66B | 23.10% |
Dec 31, 2015 | 7.84B | 28.76% |
Dec 31, 2014 | 6.09B | 88.70% |
Dec 31, 2013 | 3.23B | 52.51% |
Dec 31, 2012 | 2.12B | 6.14% |
Dec 30, 2011 | 1.99B | 52.18% |
Dec 31, 2010 | 1.31B | 36.35% |
Dec 31, 2009 | 961.30M | 13.67% |
Dec 31, 2008 | 845.70M | -29.19% |
Dec 31, 2007 | 1.19B | 12.60% |
Dec 29, 2006 | 1.06B | -5.45% |
Dec 30, 2005 | 1.12B | -3.60% |
Dec 31, 2004 | 1.16B | 107.10% |
Dec 31, 2003 | 561.90M | 55.35% |
Dec 31, 2002 | 361.70M | 63.67% |
Dec 31, 2001 | 221.00M | 27.60% |
View and export this data all the way back to 2001. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Eli Lilly and Company | 674.75B |
Johnson & Johnson | 428.49B |
AbbVie | 382.37B |
UnitedHealth Group | 316.72B |
AstraZeneca | 247.84B |
Novo Nordisk | 242.99B |
Novartis AG | 240.09B |
Abbott Laboratories | 230.70B |